Immuno-Oncology Outlook: Getting To The Root Of Head And Neck Cancer
Executive Summary
As PD-1 inhibitors march toward earlier-stage head and neck cancers, researchers consider ways to improve the precision of immunotherapy through better patient selection and combinations for this accessible tumor type.
You may also be interested in...
Merck's Keytruda Gets Benefit Of Doubt, Despite Failing in Head & Neck
Prior PD-1 failures after accelerated approval include Roche's Tecentriq in bladder cancer.
Merck & Co. Strengthening Its Strong Position In Immuno-Oncology
Additional data presented at ASCO support earlier use of Keytruda in key settings like first-line lung and bladder cancers and approval in new indications like triple-negative breast and gastric cancers. Competitor setbacks also clear the stage for Merck.
Scrip's Rough Guide To IDO
IDO has emerged at the lead suitor among new cancer immunotherapy targets to partner with PD-1/L1 inhibitors; the early data help show why big pharmas are so much on board.